Home › Non-Small Cell Lung Cancer › Idaho › Meridian
Non-Small Cell Lung Cancer clinical trials in Meridian, ID
4 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Meridian (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecruitingPhase 3
- Saint Luke's Cancer Institute - Meridian, Meridian
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
RecruitingPhase 2
- Idaho Urologic Institute-Meridian, Meridian
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
RecruitingPhase 3
- Saint Luke's Cancer Institute - Meridian, Meridian
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- Idaho Urologic Institute-Meridian, Meridian
- Saint Luke's Cancer Institute - Meridian, Meridian
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY121 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
Other studies in Meridian
- Obesity8 studies
- Overweight7 studies
- Prostate Cancer6 studies
- Acute Myeloid Leukemia6 studies
- Atherosclerosis5 studies
- Lung Cancer4 studies
- Heart Failure3 studies
- Ovarian Cancer3 studies
- Head and Neck Squamous Cell Carcinoma3 studies
- Eczema3 studies
- Cardiovascular Disease3 studies
- Colon Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.